Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4FEU8)

Drug Name
C-178 Drug Info
Synonyms
329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide
Indication
Disease Entry ICD 11 Status REF
Aicardi-Goutieres syndrome 5C55.2 Investigative [1]
Cross-matching ID
PubChem CID
2866412
TTD Drug ID
DM4FEU8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Stimulator of interferon genes protein (TMEM173)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ADU-S100 DM8HBUI Head and neck cancer 2D42 Phase 2 [3]
ADU- S100 DMM6B2Y Head and neck cancer 2D42 Phase 2 [4]
MK-1454 DMEDITW Squamous head and neck cell carcinom 2D60.0 Phase 2 [5]
IMSA101 DM43ICH Solid tumour/cancer 2A00-2F9Z Phase 1/2 [6]
BMS-986301 DMM3DBU Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
MK-2118 DMKNH8B Lymphoma 2A80-2A86 Phase 1 [8]
SB 11285 DMZ9YWG Head-neck squamous cell carcinoma 2D60.0 Phase 1 [9]
E7766 DM8TU5R Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
GSK3745417 DMRYNJD Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
TAK-676 DMCKF5J Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stimulator of interferon genes protein (TMEM173) TTT402Y STING_HUMAN Agonist [2]

References

1 Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2019 Nov;18(11):845-867.
2 Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
5 National Cancer Institute Drug Dictionary (drug name MK1454).
6 Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
7 Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
8 National Cancer Institute Drug Dictionary (drug name ML2118).
9 Clinical pipeline report, company report or official report of F-star Therapeutics.
10 E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
11 National Cancer Institute Drug Dictionary (drug name GSK3745417).
12 National Cancer Institute Drug Dictionary (drug name TAK676).